Amidst A Shortfall, The CDC And FDA Hastily Release More Doses Of RSV Treatment
Amidst A Shortfall, The CDC And FDA Hastily Release More Doses Of RSV Treatment In the midst of a persistent scarcity of nirsevimab, a paediatric RSV vaccine, the US Centres for Disease Control and Prevention have declared that over 77,000 extra doses will be provided “immediately.” The release from Thursday states that these doses would be distributed to hospitals and physician offices via the CDC’s Vaccines for Children Programme as well as commercial outlets. Beyfortus, also known as nersevimab, is a long-acting monoclonal antibody that is injected into newborns to guard against serious illness caused by respiratory syncytial virus (RSV) infections, which are the primary reason why babies end up in hospitals. Dr. Patrizia Cavazzoni, director of the US Food and Drug Administration’s Centre for Drug Evaluation and Research, stated in the announcement that “helping to ensure the availability of this preventative option to reduce the impact of RSV disease on eligible babies and young ch...